Drug Profile
Saratin
Latest Information Update: 21 Jul 2011
Price :
$50
*
At a glance
- Originator Merck KGaA
- Developer BioVascular
- Class Recombinant proteins; Salivary proteins and peptides
- Mechanism of Action Von Willebrand factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 21 Jul 2011 No development reported - Phase-I/II for Thrombosis in USA (Parenteral)
- 20 Apr 2007 Phase I/II clinical trials in Thrombosis in the USA (Parenteral)